We are live on ! Find out more
ONC

BeOne Medicines Ltd

234 hedge funds and large institutions have $8.65B invested in BeOne Medicines Ltd in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 81 increasing their positions, 79 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more call options, than puts

Call options by funds: $9.57M | Put options by funds: $2.61M

3% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 79

0% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 33

0.14% less ownership

Funds ownership: 4.13%3.99% (-0.14%)

2% less funds holding

Funds holding: 238234 (-4)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

17% less capital invested

Capital invested by funds: $10.4B → $8.65B (-$1.73B)

Holders
234
Holders Change
-4
Holders Change %
-1.68%
% of All Funds
3.94%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.15%
New
33
Increased
81
Reduced
79
Closed
33
Calls
$9.57M
Puts
$2.61M
Net Calls
+$6.96M
Net Calls Change
-$2.73M

ONC Hedge Fund Activity: Q2 2022 in Review

234 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q2 2022, worth a combined $8.65B — down 17% from $10.4B a quarter earlier.

Fund positioning in ONC was balanced in Q2 2022: 33 funds opened new positions, 33 closed out, 81 added to existing stakes and 79 trimmed.

The largest buyer was Primecap Management, adding an estimated $50.4M. The largest seller was Baillie Gifford & Co, cutting an estimated $136M.

  • 234 institutional investors held BeOne Medicines Ltd (ONC) as of Q2 2022, down from 238 in Q1 2022.
  • Funds reported $8.65B of BeOne Medicines Ltd stock for Q2 2022, down 17% quarter-over-quarter.
  • 33 funds opened new BeOne Medicines Ltd positions in Q2 2022 and 33 closed out, a net change of 0 holders.
  • The largest BeOne Medicines Ltd buyer in Q2 2022 was Primecap Management, an estimated $50.4M added.
  • The largest BeOne Medicines Ltd seller in Q2 2022 was Baillie Gifford & Co, an estimated $136M sold.

Based on aggregated 13F filings for Q2 2022.